[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine
Up 4.24% Compared to Previous Close
SK Bioscience is showing strong performance in early trading on the 20th following news that it has received approval for the Phase 3 clinical trial plan of its 21-valent pneumococcal vaccine (GBP410) in the United States.
As of 10:09 AM on the same day, SK Bioscience is trading at 51,600 KRW, up 4.24% from the previous close.
Hot Picks Today
!["Those Who Hesitated at 3,000 Still Haven't Bought" 7 Trillion-Won Asset Manager Says "Opportunities Remain" [Investment Strategies of the Wealthy] ⑦](https://cwcontent.asiae.co.kr/asiaresize/93/2026050715101553735_1778134216.jpg)
"Those Who Hesitated at 3,000 Still Haven't Bought" 7 Trillion-Won Asset Manager Says "Opportunities Remain" [Investment Strategies of the Wealthy] ⑦
- KOSPI Plunges... Foreign Media Cite Yongbum Kim's AI National Dividend Proposal as Cause
- "SK hynix Could Reach 2.8 Million Won; Why Securities Firms Are Confident That the Main Chapter of AI Has Not Even Begun Yet [Click eStock]"
- "Don't Come to Work from Tomorrow": Two Million Face Unemployment Crisis...Iran Shaken by War Shock
- Famous US Professor Calls Lee Suji's Kindergarten Parody "The Most Shocking in Korea"
On the 17th, SK Bioscience announced that it had received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of the 21-valent pneumococcal vaccine, which is being developed in collaboration with Sanofi. The global clinical trial, recruiting 7,700 participants worldwide, began dosing its first subject last month.
![[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
